NINDS will be hosting a webinar about the new NeuroNEXT ROAs
Follow the link below to view the event description and registration page:
NEW NeuroNEXT Clinical Trial ROAs have been published!
Please follow the link below to the announcement:
NEW Network SOPs Posted
The new network SOPs have been posted to the website as of March 20, 2024, which will be effective as of April 8, 2024.
Revised URGenT ROAs Have Been Published
Recently there were some revisions to the URGenT ROAs made. OTA-24-011 and OTA-24-012 replaced OTA-24-002 and OTA-24-003, respectively. The revisions were minor and mainly included updating some language in accordance with NIH policy, and inclusion of references for CDEs.
The new ROAs can be found here:
2024 Clinical Trials Methodology Course Call for Applications - Due March 4, 2024
We are pleased to announce the continuation of the NINDS Clinical Trials Methodology Course (CTMC). We are currently accepting applications for the 2024 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials. Applicants proposing large, multi-center trials will also be considered this year.
SCT Annual Meeting Registration Open
The Annual SCT Meeting registration is now open. This year it will be hosted in Boston, MA on 5/19- 5/22. Please see the attached link for more details.
https://acrobat.adobe.com/link/track?uri=urn:aaid:scds:US:79c97166-8b69-...
Notice of Information of Intent to Publish Research Opportunity Announcements for the “NeuroNEXT Clinical Trials: Stage 1 (Preliminary) and Stage 2 (Protocol) Applications (OT2)”
NOI for 2 new ROAs will be issued for NeuroNEXT Clinical Trials: Stage 1 Preliminary Application and Stage 2 Protocol Application will replace the current Notice of Funding Opportunity 'NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) PAR-21-223' expiring on March 06, 2024.
NOI: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-045.html
Gene Therapy Consortium ROAs Published
The ROAs for the Gene Therapy Consortium were published on December 4, 2023. Please find the links below. The submissions will be accepted starting on December 28, 2023 and the submission deadline is rolling.
Dr. Rossignol to Present as Part of 2022 GNEM Symposium Speaker Series
External Source:
Dr. Francis Rossignol of hte NIH National Human Genome Research Institute (NHBRI) will present as part of theGNEM Symposium Speaker Series presented by the Neuromuscular Disease Foundation. His talk, entitled "ManNAc As A Potential Therapy for GNE Myopathy - Advances and Future Directions" will include discussion of NN109. This talk is free of charge and available virtually.
Network Renewal RFAs Posted!
The RFAs for the network renewal were published on September 20, 2022. Please find links below. The deadline for grant submissions is November 21, 2022.
· Site RFA at the following link: https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-031.html
NN106 Cyto-C Clinical Trial Prospective Biomarker Study Results Published
NN106 CYTO-C Prospective biomarker study results have been published in Neurooncology Advances.
NN103 (BeatMG) Study Results Cited in NeurologyLive
Results of the NN103 study were cited in NeurologyLive.
NN103 Primary Results published in Neurology
External Source:
The results of the NN103 Beat MG have been posted online at the American Academy of Neurology.
Dixie Ecklund named to Society for Clinical Trials Class of 2021 Fellows
External Source:
Congratulations to Dixie Ecklund, Director of Operations at the NeuroNEXT DCC, for being selected to join the Society for Clinical Trials Class of 2021 Fellows! Ecklund will be recognized as a new inductee at the virtual SCT annual meeting in May.
NeuroNEXT Fellow and CTMC Alum highlighted at Wake Forest CTSI
A NeuroNEXT Fellowship can help young neurology faculty develop their careers, as highlighted by Wake Forest University in an article about former NeuroNEXT Fellow and Clinical Trials Methodology Course (CTMC) alumnus Dr. Heidi Munger Clay (see link below).
CTMC: 2021 Call for Applications
External Source:
We are pleased to announce that the NINDS Clinical Trials Methodology Course (CTMC) is accepting applications for the 2021 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials.
Course:
NeuroNEXT 2020 Annual Meeting
NeuroNEXT Leadership would like to thank everyone for another successful annual meeting! We were able to celebrate several milestones in our virtual format, including:
Update: Clinical Trials Methodology Course 2020
External Source:
A message from the Executive Committee of the Clinical Trials Methodology Course (CTMC):
Due to the global COVID-19 (Coronavirus) pandemic and the number of uncertainties that accompany such a health crisis, the Clinical Trials Methodology Course (CTMC) Executive Committee has decided to postpone the Course until next year.
NeuroNEXT Response to COVID 19
A message from Merit Cudkowicz and Christopher Coffey, March 18, 2020:
Dear NeuroNEXT PIs and Coordinators,
We would like to share some updates regarding NeuroNEXT Network response to the evolving COVID-19 crisis.
Joyce Moran elected Fellow of the ACRP
The Association of Clinical Research Professionals (ACRP) has selected NeuroNEXT Project Manager